Boulder, CO, United States of America

Robert D Groneberg

This inventor holds 20 USPTO granted patents and 3 published patent applications, plus 5 CIPO patents and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Array Biopharma Inc., Amgen Inc., Aventis Pharma Deutschland, Gmbh. Active years: 2000-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Robert D Groneberg. Retrieved from https://idiyas.com/inventor/robert-d-groneberg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 20 

% Patents Active = 65.0

 

 

Average Co-Inventor Count = 7.1

ph-index = 5

Forward Citations = 153(Granted Patents)


Location History:

  • Collegeville, PA (US) (2000 - 2003)
  • Boulder, CO (US) (2003 - 2016)

Company Filing History:


Years Active: 2000-2016

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Benzoazepines
Kinase Inhibitors
P38 Inhibitors
Imidazopyrimidines
Amino Compounds
Phosphatase Inhibitors
Therapeutic Uses
Cyclic Amines
Aryl Derivatives
Oxoazaheterocyclic
Thiocarboxylic Acids
Resin Compounds
20 patents (USPTO):Explore Patents

Title: The Innovative Journey of Robert D. Groneberg: Pioneering Technology for a Brighter Future

Introduction:

Robert D. Groneberg, a visionary from Boulder, CO, has left an indelible mark on the world of technology with his relentless pursuit of innovation and dedication to creating meaningful change through his inventions. His work serves as an inspiration for future generations of inventors to think beyond the conventional and explore new possibilities in the realm of science and technology.

Latest Patents:

Groneberg's latest patents showcase his commitment to advancing healthcare and addressing critical medical needs. One of his patents focuses on substituted benzoazepines as toll-like receptor modulators, offering new avenues for treating diseases such as cancer, autoimmune disorders, and infectious diseases. Another patent highlights 5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases, providing innovative solutions for autoimmune diseases, inflammatory disorders, and hematologic malignancies.

Career Highlights:

Throughout his illustrious career, Groneberg has collaborated with leading companies at the forefront of biopharmaceutical research. He has contributed his expertise to Array Biopharma Inc. and Aventis Pharma Deutschland, Gmbh, where his innovative spirit and groundbreaking inventions have pushed the boundaries of scientific discovery.

Collaborations:

Groneberg's impact extends beyond his individual achievements, as he has collaborated with esteemed colleagues such as Martha E. Rodriguez and Darren Martin Harvey. Together, they have worked towards developing cutting-edge technologies that have the potential to revolutionize the field of medicine and improve the lives of countless individuals worldwide.

Conclusion:

In conclusion, Robert D. Groneberg stands as a true pioneer in the world of technology, whose unwavering dedication to innovation has paved the way for groundbreaking discoveries in healthcare and beyond. His legacy serves as a testament to the power of creativity, collaboration, and perseverance in driving meaningful change and shaping a brighter future for generations to come.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…